|Table of Contents|

Construction of prediction model of non-small cell lung cancer patients based on serum tumor markers

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 14
Page:
2554-2560
Research Field:
Publishing date:

Info

Title:
Construction of prediction model of non-small cell lung cancer patients based on serum tumor markers
Author(s):
GUO Jiajia; GAO Yongyue; MAO Zhezhe
Handan Central Hospital,Hebei Handan 056002,China.
Keywords:
non-small cell lung cancer; tumor markers; prognosis; prediction model
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.14.010
Abstract:
Objective:To analyze the effects of serum tumor markers on postoperative prognosis of patients with non-small cell lung cancer (NSCLC),and build a Nomogram prediction model based on this analysis.Methods:A total of 143 patients with NSCLC admitted to our hospital from January 2017 to February 2020 were selected and divided into death group (n=51) and survival group (n=92) according to their survival status three years after surgery.General clinical data of the two groups were compared,and multivariate COX regression risk model was used to analyze the independent risk factors affecting the prognosis of patients with NSCLC.A Nomogram prediction model was constructed by R software "rms" package.Results:There were statistically significant differences in age,maximum tumor diameter,tumor stage,degree of differentiation,vascular cancer thrombus,CEA,NSE,AFP,CA125 and CA199 between 2 groups (P＜0.05).Differentiation degree (low differentiation),CEA(>8.45 ng/mL),NSE(>18.17 ng/mL) and CA199(>40.73 U/mL) were independent risk factors for prognosis of NSCLC patients(P＜0.05).The C-index of Nomogram prediction model was 0.847(0.807~0.886),and the calibration curve was close to the ideal curve.The decision curve results showed that the prediction model provided additional clinical net benefit when the risk threshold was>0.13.Conclusion:Low differentiation,high CEA,high NSE,and high CA199 are independent risk factors for death in patients with NSCLC.This Nomogram model will provide important strategic guidance for prevention and treatment of prognosis in patients with NSCLC.

References:

［1］郭欣欣,谢赫男.Ⅰ期非小细胞肺癌老年患者微创术后生存的影响因素［J］.实用癌症杂志,2022,37(3):428-430. GUO XX,XIE HN.Influencing factors of survival after minimally invasive operation in elderly patients with stage Ⅰnon-small cell lung cancer［J］.The Practical Journal of Cancer,2022,37(3):428-430.
［2］郭爱霞,王珍,孙倩,等.CA72-4、CA15-3、AFP及NSE评估非小细胞肺癌患者术后预后的价值观察［J］.实用癌症杂志,2023,38(3):422-426. GUO AX，WANG Z,SUN Q,et al.Value of CA72-4,CA15-3,AFP and NSE on evaluating postoperative prognosis of patients with non-small cell lung cancer［J］.The Practical Journal of Cancer,2023,38(3):422-426.
［3］陈春来.Ⅰ期非小细胞肺癌老年患者微创术后生存的影响因素分析［J］.广西医科大学学报,2019,36(9):1451-1455. CHEN CL.The factors influencing postoperative survival of stage Ⅰ non-small cell lung cancer［J］.Journal of Guangxi Medical University,2019,36(9):1451-1455.
［4］高建娥,盖晓静.N2期非小细胞肺癌患者行根治性切除术预后的影响因素［J］.中国卫生工程学,2022,21(3):508-509,512. GAO JE,GAI XJ.Prognostic factors of patients with N2 stage non-small cell lung cancer undergoing radical resection［J］.Chinese Journal of Public Health Engineering,2022,21(3):508-509,512.
［5］冯雨,崔东,张会民,等.外周血循环肿瘤细胞联合血清肿瘤标志物检测在非小细胞肺癌患者中的临床意义［J］.实用医院临床杂志,2022,19(6):31-33. FENG Y,CUN D,ZHANG HM,et al.Clinical significance of peripheral blood CTCs combined with serum tumor markers in pa-tients with non-small cell lung cancer［J］.Practical Journal of Clinical Medicine,2022,19(6):31-33.
［6］张桐睿,李军,申敏,等.CT影像组学结合肺癌血清肿瘤标志物预测非小细胞肺癌亚型的初步研究［J］.中国CT和MRI杂志,2023,21(3):65-67. ZHANG TR,LI J,SHEN M,et al.Apreliminary study of CT radiomic combined with serum tumor markers in predicting subtypes of non-small cell lung cancer［J］.Chinese Journal of CT and MRI,2023,21(3):65-67.
［7］谢占强,程可洛,余丽双,等.吉非替尼靶向治疗非小细胞肺癌前后血清肿瘤标志物的改变及临床意义［J］.中国医师杂志,2018,20(6):889-892. XIE ZQ,CHEN KL,YU LS,et al.Changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy［J］.Journal of Chinese Physician,2018,20(6):889-892.
［8］韩蕃颉,王海滨,苏新云,等.3项血清肿瘤标志物、SAA及DCLK1联合检测在非小细胞癌患者预后判断中的价值［J］.国际检验医学杂志,2021,42(17):2154-2157. HAN FJ,WANG HB,SUN XY,et al.Value of combined detection of 3 serum tumor markers,SAA and DCLK1 in prognosis of patients with non-small cell carcinoma［J］.International Journal of Laboratory Medicine,2021,42(17):2154-2157.
［9］杨善岚,王楠,李洋洋,等.非小细胞肺癌患者手术预后影响因素及预测模型构建［J］.中华肿瘤防治杂志,2022,29(23):1676-1684. YANG SL,WANG N,LI YY,et al.Influencing factors and prediction model construction of prognosis in patients with non-small cell lung cancer undergoing surgery［J］.Chinese Journal of Cancer Prevention and Treatment,2022,29(23):1676-1684.
［10］COSTER JN,GROTH SS.Surgery for locally advanced and oligometastatic non-small cell lung cancer［J］.Surg Oncol Clin N Am,2020,29(4):543-554.
［11］DONINGTON J,SCHUMACHER L,YANAGAWA J.Surgical issues for operable early-stage non-small-cell lung cancer［J］.J Clin Oncol,2022,40(6):530-538.
［12］钱斌,俞巍.早期NSCLC患者全胸腔镜肺叶切除术的临床应用研究进展［J］.现代肿瘤医学,2021,29(12):2195-2201. QIAN Bin,YU Wei.Advances in clinical application of total thoracoscopic lobectomy in early NSCLC patients［J］.Modern Oncology,2021,29(12):2195-2201.
［13］PENNELL NA,ARCILA ME,GANDARA DR,et al.Biomarker testing for patients with advanced non-small cell lung cancer:real-world issues and tough choices［J］.Am Soc Clin Oncol Educ Book,2019,39:531-542.
［14］杨桂学,李冉华,曾涛,等.肿瘤标志物预测NSCLC患者EGFR突变概率数学模型的建立与评价［J］.现代肿瘤医学,2019,27（21）:3816-3820. YANG Guixue,LI Ranhua,ZENG Tao,et al.Establishment and evaluation of a mathematical model for predicting the EGFR gene mutation probability of non-small cell lung cancer with tumor markers［J］.Modern Oncology,2019,27（21）:3816-3820.
［15］CHEN X,FANG M,DONG D,et al.A radiomics signature in preoperative predicting degree of tumor differentiation in patients with non-small cell lung cancer［J］.Acad Radiol,2018,25(12):1548-1555.
［16］朱杰,周攀,舒圣,等.非小细胞肺癌组织HK2、PKM2蛋白表达与术后复发的临床关系分析［J］.局解手术学杂志,2023,32(2):154-159. ZHU J,ZHOU P,SHU S,et al.Expression of HK2 and PKM2 proteins in non-small cell lung cancer tissues and their clinical relationships with postoperative recurrence［J］.Journal of Regional Anatomy and Operative Surgery,2023,32(2):154-159.
［17］杨文龙,范懿魏,陆世春,等.直径≤3 cm非小细胞肺癌发生单独N1淋巴结转移的危险因素分析［J］.临床肺科杂志,2023,28(3):331-335. YANG WL,FAN YW,LU SC,et al.Risk factors analysis of single N1 lymph node metastasis in non-small cell lung cancer with diameter ≤3 cm［J］.Journal of Clinical Pulmonary Medicine,2023,28(3):331-335.
［18］杨芳,王雅,梁丽红,等.CEA、AFP及CYFRA21-1在NSCLC中的表达及与病理特征和预后的关系［J］.分子诊断与治疗杂志,2022,14(4):577-580. YANG F,WANG Y,LIANG LH,et al.Relationship between the expression of CEA,AFP and CYFRA21-1 in NSCLC and path-ological characteristics and prognosis［J］.Journal of Molecular Diagnosis and Therapy,2022,14(4):577-580.
［19］刘颖,任中海,张英丽.血清神经元特异性烯醇化酶、组织多肽抗原、胃泌素释放肽前体对非小细胞肺癌的诊断价值研究［J］.实用癌症杂志,2022,37(5):752-754,757. LIU Y,REN ZH,ZHANG YL.The value of serum NSE,ProGRP and TPA in non-traumatic diagnosis of patients with NSCLC［J］.The Practical Journal of Cancer,2022,37(5):752-754,757.
［20］应晓珍,林霞,鲍黎明,等.非小细胞肺癌患者血清癌胚抗原、神经元特异性烯醇化酶、胃泌素释放肽前体水平与患者预后关系研究［J］.中国卫生检验杂志,2019,29(10):1211-1213. YING XZ,LIN X,BAO LM,et al.Relationship between serum CEA,NSE and proGRP levels and prognosis in patients with non-small cell lung cancer［J］.Chinese Journal of Health Laboratory Technology,2019,29(10):1211-1213.
［21］王莉,赵莹,张辉,等.多种血清肿瘤标志物联合检测诊断非小细胞肺癌的价值分析［J］.河北医药,2019,41(17):2594-2597. WANG L,ZHAO Y,ZHANG H,et al.Clinical value of combined detection of multiple markers of serum tumor in diagnosis of non-small cell lung cancer［J］.Hebei Medical Journal,2019,41(17):2594-2597.
［22］付伟,王松,米祖云,等.联合检测血清CA125、CA199在消化系统恶性肿瘤诊断中的价值［J］.现代肿瘤医学,2017,25(21):3468-3470. FU Wei,WANG Song,MI Zuyun,et al.The diagnostic value of combination serum levels of CA125 and CA199 in digestive system cancer［J］.Modern Oncology,2017,25(21):3468-3470.
［23］杨波,陈洋,关静文,等.五项肿瘤标志物与非小细胞肺癌患者临床病理特征及预后的相关性研究［J］.广州医科大学学报,2023,51(01):40-44. YANG B,CHEN Y,GUAN JW,et al.Correlation of five tumor markers with clinicopathological features and prognosis of NSCLC patients［J］.Academic Journal of Guangzhou Medical College,2023,51(01):40-44.
［24］ZUO Z,ZHANG G,SONG P,et al.Survival Nomogram for stage Ib non-small-cell lung cancer patients,based on the SEER database and an external validation cohort［J］.Ann Surg Oncol,2021,28(7):3941-3950.

Memo

Memo:
河北省医学科学研究课题计划项目(编号：20220552)
Last Update: 1900-01-01